氯己定、莫匹罗星与生理盐水局部应用预防腹膜透析相关感染的多中心随机双盲对照试验方案
本研究为多中心随机双盲活性对照试验方案,拟在泰国3个腹膜透析中心纳入354例成人腹膜透析患者,随机分为2%氯己定葡萄糖酸盐贴片组、莫匹罗星软膏组或生理盐水常规出口处护理组。主要结局为首次腹膜透析相关感染时间及感染率差异,随访至停止腹膜透析或满24个月,并开展成本-效用分析。
要点
- 比较2%氯己定贴片、莫匹罗星软膏与生理盐水常规护理预防腹膜透析相关感染。
- 主要结局为首次感染时间及组间感染率差异,随访至停止腹膜透析或24个月。
- 次要结局包括导管移除率、技术失败率、金黄色葡萄球菌定植率、医疗费用及不良反应。
核心结论
- 该试验旨在为泰国腹膜透析人群预防腹膜透析相关感染提供新的临床与成本效果证据。
研究设计与样本
- 多中心、随机、双盲、活性对照临床试验方案,在泰国3个腹膜透析中心纳入354例18岁及以上终末期肾病腹膜透析患者。
- 按计算机生成随机分配序列分为2%氯己定葡萄糖酸盐贴片组、莫匹罗星软膏组或生理盐水常规出口处护理组,随访至停止腹膜透析或满24个月。
关键数值与推荐
- 主要结局为首次腹膜透析相关感染(出口处/隧道感染或腹膜炎)时间及组间腹膜透析相关感染率总体差异。
- 次要结局包括感染相关导管移除率与腹膜透析技术失败率、鼻腔及出口处金黄色葡萄球菌定植率、医疗费用、皮肤反应与不良事件。
- 计划开展成本-效用分析,采用Markov模拟模型估算20年时间 horizon 的总成本与质量调整生命年(QALYs),并计算每获得一个QALY的增量成本效果比(泰铢与美元)。
临床怎么用
- 若试验证实某局部抗菌方案优于生理盐水常规护理,可为腹膜透析出口处护理提供循证选择。
局限性
- 本文为试验方案,尚无结果数据;研究人群为泰国腹膜透析患者,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Current international guidelines recommend the use of a daily topical exit-site antimicrobial to prevent peritoneal dialysis (PD)-related infections. Although nonantibiotic-based therapies are appealing because they may limit antimicrobial resistance, no controlled trials have been conducted to compare topical antimicrobial agents with usual exit-site care for the prevention of PD-related infections among the Thai PD population. We propose a controlled three-arm trial to examine the efficacy and safety of a daily chlorhexidine gluconate-impregnated patch versus mupirocin ointment versus usual exit-site care with normal saline for the prevention of PD-related infections. METHODS/DESIGNS: This study is a randomized, double-blind, multicenter, active-controlled, clinical trial. Adult patients aged 18 years or older who have end-stage kidney disease and are undergoing PD will be enrolled at three PD Centers in Thailand. A total of 354 PD patients will be randomly assigned to either the 2% chlorhexidine gluconate-impregnated patch, mupirocin ointment, or usual exit-site care with normal saline dressing according to a computer-generated random allocation sequence. Participants will be followed until discontinuation of PD or completion of 24 months. The primary study outcomes are time to first PD-related infection (exit-site/tunnel infection or peritonitis) event and the overall difference in PD-related infection rates between study arms. Secondary study outcomes will include (i) the rate of infection-related catheter removal and PD technique failure, (ii) rate of nasal and exit-site Staphylococcus aureus colonization, (iii) healthcare costs, and (iv) skin reactions and adverse events. We plan to conduct a cost-utility analysis alongside the trial from the perspectives of patients and society. A Markov simulation model will be used to estimate the total cost and health outcome in terms of quality-adjusted life years (QALYs) over a 20-year time horizon. An incremental cost-effectiveness ratio in Thai Baht and U.S. dollars per QALYs gained will be illustrated. A series of probabilistic sensitivity analyses will be conducted to assess the robustness of the cost-utility analysis findings. DISCUSSION: The results from this study will provide new clinical and cost-effectiveness evidence to support the best strategy for the prevention of PD-related infections among the Thai PD population. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02547103. Registered on September 11, 2015.
引用
- Nochaiwong S, Ruengorn C, Noppakun K, et al. Comparative Effectiveness of Local Application of Chlorhexidine Gluconate, Mupirocin Ointment, and Normal Saline for the Prevention of Peritoneal Dialysis-related Infections (COSMO-PD Trial): a multicenter randomized, double-blind, controlled protocol. Trials. 2019. PMID: 31856900. doi:10.1186/s13063-019-3953-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。